Patents by Inventor Ian Farquhar Campbell McKenzie
Ian Farquhar Campbell McKenzie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110033493Abstract: The present invention provides a method of immunising a subject comprising the step of administering a composition comprising an antigen and a carbohydrate polymer comprising mannose to a mucosal site of the subject, methods of use of the composition for vaccination and sterilization and use of the composition in manufacturing a medicament.Type: ApplicationFiled: June 11, 2010Publication date: February 10, 2011Applicants: AUSTIN RESEARCH INSTITUTE, THE, MELBOURNE, UNIVERSITY OF, THEInventors: Ian Farquhar Campbell McKenzie, Geoffrey Allan Pietersz, Christina Cheers, John Stambas
-
Publication number: 20100119514Abstract: An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitising a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.Type: ApplicationFiled: November 16, 2009Publication date: May 13, 2010Applicant: The Macfarlane Burnet Institute for Medical Research and Public Health Ltd.Inventors: Ian Farquhar Campbell McKenzie, Pei Xiang Xing, Xiu Feng Hu
-
Publication number: 20090317414Abstract: A cancer vaccine, and a composition for the ex vivo priming of dendritic cells, is disclosed which comprises a MUC1 T cell epitope-derived peptide or peptide analogue capable of provoking a cytotoxic T cell immune response. Particular MUC1 T cell epitope-derived peptides disclosed include TTAPPVHGL, STAPPVHGL, STAPPAHGL, TTAPPAHGV and SAPDTYPAL.Type: ApplicationFiled: July 25, 2007Publication date: December 24, 2009Applicant: 4G VACCINES PTY LTDInventors: Geoffrey Allan Pietersz, Vasso Apostolopoulos, Ian Farquhar Campbell McKenzie
-
Publication number: 20090123470Abstract: An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitizing a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.Type: ApplicationFiled: November 20, 2007Publication date: May 14, 2009Applicant: The Macfarlane Burnet Istitute for Medical Research and Public Health Ltd.Inventors: Ian Farquhar Campbell McKenzie, Pei Xiang Xing, Xiu Feng Hu
-
Patent number: 7318924Abstract: An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitizing a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.Type: GrantFiled: March 26, 2002Date of Patent: January 15, 2008Assignee: The Austin Research InstituteInventors: Ian Farquhar Campbell McKenzie, Pei-Xiang Xing, Xiu Feng Hu
-
Patent number: 7001998Abstract: The invention relates to nucleic acids which encode glycosyltransferase and are useful in producing cells and organs from one species which may be used for transplantation into a recipient of another species. It also relates to the production of nucleic acids which, when present in cells of a transplanted organ, result in reduced levels of antibody recognition of the transplanted organ.Type: GrantFiled: August 1, 1997Date of Patent: February 21, 2006Assignee: The Austin Research InstituteInventors: Ian Farquhar Campbell McKenzie, Mauro Sergio Sandrin
-
Publication number: 20040213781Abstract: The present invention generally relates to molecules having Fc binding ability such as those with Fc receptor-like activity. The present invention also relates to the molecules, nucleic acids encoding the molecules, antagonist compounds, pharmaceutical compositions comprising the molecules and compounds, methods for testing potential antagonists, methods for producing the polypeptides, methods of treatment of disease and other aspects.Type: ApplicationFiled: July 31, 2003Publication date: October 28, 2004Inventors: Phillip Mark Hogarth, Ian Farquhar Campbell McKenzie, Ross Ian Baker, Mark Darren Hulett, Maree Sharne Powell
-
Publication number: 20020081654Abstract: A nucleic acid construct encoding a peptide with hydrolase activity and a heterologous localization signal which locates the peptide, upon expression of the construct in a cell, to a cellular location proximal to the cellular site of a glycosylated agent or a glycosylating agent. The construct can be used to produce, for example, organs suitable for transplantation which show reduced levels of the epitope Gal&agr;(1,3)Gal.Type: ApplicationFiled: April 6, 2001Publication date: June 27, 2002Inventors: Mauro Sergio Sandrin, Ian Farquhar Campbell McKenzie, Narin Osman
-
Publication number: 20010055584Abstract: The invention relates to nucleic acids which encode glycosyltransferase and are useful in producing cells and organs from one species which may be used for transplantation into a recipient of another species. It also relates to the production of nucleic acids which, when present in cells of a transplanted organ, result in reduced levels of antibody recognition of the transplanted organ.Type: ApplicationFiled: March 31, 1998Publication date: December 27, 2001Inventors: IAN FARQUHAR CAMPBELL MCKENZIE, MAURO SERGIO SANDRIN
-
Patent number: 5798097Abstract: Immunoglobulin conjugates, comprising idarubicin (Ida) conjugated to a monoclonal antibody or fragment thereof comprising at least one of the antigen binding sites of the antigen, are useful for treating a human or other animal suffering from a cancer or for depleting a subset of T lymphocytes from a population of cells.Type: GrantFiled: April 11, 1995Date of Patent: August 25, 1998Assignee: Pharmacia & Upjohn S.p.A.Inventors: Ian Farquhar Campbell McKenzie, Geoffrey Allan Pietersz, Mark John Smyth